Jazz Pharmaceuticals said its phase 3 Lagoon trial evaluating Zepzelca as a second-line treatment for metastatic small-cell lung cancer (SCLC) failed to meet its primary endpoint of overall survival, creating uncertainty around the drug’s accelerated approval for previously treated patients.
The Lagoon study assessed Zepzelca both as a standalone treatment and in combination with irinotecan. The control arm consisted of physician-selected chemotherapy, either topotecan or irinotecan. All treatments involved in the study were chemotherapy-based regimens.
The results mark another setback for Zepzelca in the second-line SCLC setting. The drug received accelerated approval for previously treated SCLC based on tumor response data from a phase 2 single-arm study. A previous phase 3 confirmatory study, Atlantis, also failed to demonstrate an overall survival advantage for Zepzelca combined with doxorubicin compared with the physician’s choice of chemotherapy.
Despite the Atlantis outcome, the FDA allowed the drug to remain on the market. In 2022, when rejecting a citizen petition seeking the drug’s withdrawal, the agency noted that Atlantis had used a lower dose of Zepzelca than the approved regimen and cited the unmet medical need in second-line SCLC. In the Lagoon trial, Zepzelca monotherapy was administered at its approved dose, while the combination arm used a lower dose of the drug.
According to Jazz, patients treated with Zepzelca alone experienced a 19% higher risk of death compared with those in the control group. Median overall survival was 8.7 months for the monotherapy arm versus 10.7 months for patients receiving control treatments.
The Zepzelca-irinotecan combination produced a numerical improvement in overall survival but did not achieve statistical significance. Jazz reported a 9.8% reduction in the risk of death in the overall study population.
The trial enrolled a broader patient population than the phase 2 study by including individuals with a history of brain metastases. Jazz stated, “Efficacy of Zepzelca in the subset of patients without a history of CNS involvement was more comparable to the control arm, which performed better than historical precedent.”
Among patients without brain metastases, median overall survival was 9.6 months with Zepzelca monotherapy and 10.7 months in the control group. Patients treated with the Zepzelca-irinotecan combination achieved a median overall survival of 11.1 months, accompanied by a 7.8% reduction in the risk of death.
Jazz said it has submitted the Lagoon data to the FDA and plans to discuss next steps regarding the drug’s second-line indication. The company licenses U.S. rights to Zepzelca from PharmaMar, which conducted the Lagoon trial.
The trial outcome does not affect Zepzelca’s separate approval as a first-line maintenance treatment. In 2025, the FDA granted full approval to Zepzelca in combination with Roche’s Tecentriq for patients with extensive-stage SCLC whose disease had not progressed after initial chemotherapy. That approval was supported by the phase 3 IMforte study, which showed the combination reduced the risk of death by 27% compared with Tecentriq alone.
The Phase 3 study was closely watched by investors, clinicians, and patient advocacy groups because it had the potential to establish a new standard of care in the second-line treatment setting. Achieving an overall survival benefit is considered one of the most important measures of success in oncology trials, as it directly reflects the impact of a therapy on patient longevity.
Failure to meet this endpoint can influence regulatory strategies, commercial expectations, and future development plans. However, it does not necessarily diminish the scientific value of the data collected during the study.
The Ongoing Challenge of Small Cell Lung Cancer
Small cell lung cancer remains one of the most aggressive and difficult-to-treat forms of cancer. The disease often responds to initial treatment but frequently returns in a more resistant form. As a result, patients who experience disease progression after first-line therapy typically face limited treatment options and poor long-term outcomes.
Zepzelca Remains Part of Oncology Strategy
Despite the setback, Zepzelca continues to be an important component of broader oncology research efforts. The experience gained from the Lagoon trial will help shape future clinical programs and inform the development of next-generation cancer therapies.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
